PharmChem, Inc. (PCHM) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PCHM representa a PharmChem, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 49/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026PharmChem, Inc. (PCHM) Resumen de Asistencia Médica y Tuberías
PharmChem, Inc., based in Fort Worth, Texas, develops and provides the PharmChek Sweat Patch, an alternative drug testing method utilizing sweat for the detection of cocaine, opiates, amphetamines, PCP, and marijuana, positioning itself within the medical diagnostics sector.
Tesis de Inversión
PharmChem, Inc. presents a focused investment opportunity within the niche market of sweat-based drug detection. With a market capitalization of $0.02 billion and a P/E ratio of 18.80, the company demonstrates profitability, supported by a gross margin of 64.2% and a profit margin of 19.7%. The company's beta of 0.67 suggests lower volatility compared to the broader market. Growth catalysts include potential expansion into new geographic markets and increased adoption of sweat-based testing methodologies. However, the company faces risks associated with regulatory approvals, competition from established drug testing methods, and its small size. The absence of a dividend may deter some investors. The investment thesis hinges on PharmChem's ability to maintain its market share and capitalize on the growing demand for alternative drug testing solutions.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.02 billion indicates a micro-cap company with potential for high growth but also higher risk.
- P/E ratio of 18.80 suggests the company is trading at a reasonable valuation compared to its earnings.
- Profit margin of 19.7% demonstrates strong profitability and efficient operations.
- Gross margin of 64.2% indicates a significant competitive advantage in its niche market.
- Beta of 0.67 suggests lower volatility compared to the broader market, potentially offering a more stable investment.
Competidores y Pares
Fortalezas
- Proprietary PharmChek Sweat Patch technology
- Alternative to traditional urine testing
- Established presence in a niche market
- High gross margin of 64.2%
Debilidades
- Small company size with only 9 employees
- Limited product line focused on a single product
- Reliance on a niche market with potential regulatory risks
- Lack of dividend may deter some investors
Catalizadores
- Upcoming: Potential partnerships with substance abuse treatment centers to integrate PharmChek Sweat Patch into treatment programs.
- Upcoming: Expansion into new geographic markets, such as Europe and Asia, to increase revenue and market share.
- Ongoing: Increasing awareness of the benefits of sweat-based drug testing compared to traditional methods.
- Ongoing: Rising demand for alternative drug testing solutions in various sectors, including workplace and law enforcement.
- Upcoming: Development and launch of new sweat-based tests for other drugs of abuse and medical conditions.
Riesgos
- Potential: Regulatory changes affecting the acceptance and use of sweat-based drug testing.
- Potential: Competition from established drug testing methods and larger companies.
- Ongoing: Limited financial resources and small company size may hinder growth and expansion.
- Potential: Risk of product obsolescence due to technological advancements in drug testing.
- Ongoing: Dependence on a single product (PharmChek Sweat Patch) increases vulnerability to market changes.
Oportunidades de crecimiento
- Expansion into International Markets: PharmChem can explore opportunities to expand its market reach beyond the United States. The global drug testing market is expected to grow, driven by increasing awareness of drug abuse and stricter regulations in various countries. Entering new markets, such as Europe and Asia, could significantly increase PharmChem's revenue and market share. Timeline: 2-3 years.
- Partnerships with Substance Abuse Treatment Centers: Collaborating with substance abuse treatment centers can provide PharmChem with a steady stream of customers and enhance its brand recognition. By integrating the PharmChek Sweat Patch into treatment programs, PharmChem can demonstrate its effectiveness and reliability, leading to increased adoption. Timeline: 1-2 years.
- Development of New Sweat-Based Tests: PharmChem can invest in research and development to expand its portfolio of sweat-based tests. This could include tests for other drugs of abuse, as well as tests for medical conditions and biomarkers. By diversifying its product line, PharmChem can reduce its reliance on a single product and tap into new markets. Timeline: 3-5 years.
- Integration with Telehealth Platforms: As telehealth becomes increasingly prevalent, PharmChem can explore opportunities to integrate its sweat patch technology with telehealth platforms. This would allow healthcare providers to remotely monitor patients for drug use, improving adherence to treatment plans and reducing the risk of relapse. Timeline: 2-3 years.
- Focus on Workplace Drug Testing Programs: PharmChem can target companies and organizations that require drug testing for their employees. The PharmChek Sweat Patch offers a convenient and non-invasive alternative to urine testing, which may be more appealing to employees. By focusing on this market segment, PharmChem can secure long-term contracts and generate recurring revenue. Timeline: 1-2 years.
Oportunidades
- Expansion into international markets
- Partnerships with substance abuse treatment centers
- Development of new sweat-based tests
- Integration with telehealth platforms
Amenazas
- Competition from established drug testing methods
- Regulatory changes affecting sweat-based testing
- Potential for product obsolescence due to technological advancements
- Economic downturn affecting demand for drug testing services
Ventajas competitivas
- Proprietary sweat patch technology
- Alternative to traditional urine testing
- Established presence in the niche market of sweat-based drug detection
Acerca de PCHM
PharmChem, Inc., headquartered in Fort Worth, Texas, focuses on providing innovative drug detection solutions. The company's primary product is the PharmChek Sweat Patch, a non-invasive method for detecting the presence of drugs of abuse. Unlike traditional urine testing, the PharmChek Sweat Patch uses sweat as the sample source, offering a less intrusive and potentially more convenient option for drug screening. The patch is designed to detect cocaine, opiates, amphetamines, PCP, and marijuana. PharmChem's technology caters to various sectors, including substance abuse treatment programs, law enforcement, and workplace drug testing. The company aims to provide a reliable and accurate alternative to conventional drug testing methods, addressing the challenges associated with urine sample collection and potential adulteration. While the company's history and founding details are not available, its current focus remains on the production and distribution of the PharmChek Sweat Patch. PharmChem operates primarily within the United States, focusing on markets where sweat-based drug testing is accepted and utilized. The company's small size, with only 9 employees, suggests a niche market focus and a lean operational structure.
Qué hacen
- Provides PharmChek Sweat Patch for drug detection.
- Offers an alternative to urine testing.
- Detects cocaine, opiates, amphetamines, PCP, and marijuana.
- Uses sweat as the source for drug testing.
- Serves substance abuse treatment programs.
- Serves law enforcement agencies.
- Serves workplace drug testing programs.
Modelo de Negocio
- PharmChem generates revenue through the sale of PharmChek Sweat Patches.
- The company targets substance abuse treatment centers, law enforcement, and employers.
- PharmChem focuses on providing a convenient and reliable alternative to traditional urine testing.
Contexto de la Industria
PharmChem, Inc. operates within the medical diagnostics and research industry, specifically focusing on drug testing solutions. The drug testing market is driven by factors such as increasing drug abuse rates, workplace safety regulations, and law enforcement needs. The industry includes various testing methods, including urine, blood, hair, and sweat analysis. PharmChem's PharmChek Sweat Patch competes with established urine testing methods and other alternative testing technologies. The company's success depends on its ability to differentiate its product through accuracy, convenience, and cost-effectiveness. The competitive landscape includes companies offering a range of drug testing products and services, requiring PharmChem to maintain a strong market position through innovation and strategic partnerships.
Clientes Clave
- Substance abuse treatment centers
- Law enforcement agencies
- Workplace drug testing programs
Finanzas
Gráfico e información
Precio de la acción de PharmChem, Inc. (PCHM): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Highs On Tuesday
· 17 dic 2019
-
Stocks That Hit 52-Week Highs On Tuesday
· 23 sept 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para PCHM.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para PCHM.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de PCHM en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Thompson Clark CPA
CEO
Thompson Clark is a Certified Public Accountant (CPA) and serves as the CEO of PharmChem, Inc. With a background in accounting and finance, Clark brings financial expertise to the company's leadership. His experience likely includes financial management, strategic planning, and compliance. As the head of PharmChem, Clark is responsible for overseeing the company's operations, driving growth, and ensuring financial stability. He manages a small team of 9 employees.
Historial: As CEO of PharmChem, Thompson Clark has overseen the company's operations in providing the PharmChek Sweat Patch for drug detection. His leadership has contributed to the company's profitability, as evidenced by its profit margin of 19.7%. Specific milestones and strategic decisions under his leadership are not available, but his role is crucial in guiding the company's growth and maintaining its market position.
Información del mercado OTC de PCHM
The OTC Other tier represents the lowest tier of the OTC market, indicating that PharmChem, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors and may be subject to greater risks. Trading on the OTC Other tier differs significantly from trading on major exchanges like the NYSE or NASDAQ, where companies must adhere to strict listing standards and reporting obligations. The OTC Other tier is often populated by shell companies, defunct companies, or companies with questionable financials.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in PCHM.
- Low liquidity can make it difficult to buy or sell shares.
- Potential for high price volatility due to low trading volume.
- Risk of delisting or trading suspension due to non-compliance with OTC regulations.
- Higher risk of fraud or manipulation compared to stocks listed on major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Check the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile for any warnings or disclosures.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Confirm the company's contact information and physical address.
- The company has been in operation for several years.
- PharmChem has a specific product (PharmChek Sweat Patch) with a defined application.
- The company has a CEO (Thompson Clark CPA) with a professional background.
- PharmChem has a small team of employees (9), suggesting a real operational presence.
- The company's product addresses a specific need in the drug testing market.
Preguntas Comunes Sobre PCHM
¿Cuáles son los factores clave para evaluar PCHM?
PharmChem, Inc. (PCHM) actualmente tiene una puntuación IA de 49/100, indicando puntuación baja. Fortaleza clave: Proprietary PharmChek Sweat Patch technology. Riesgo principal a monitorear: Potential: Regulatory changes affecting the acceptance and use of sweat-based drug testing.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de PCHM?
PCHM actualmente puntúa 49/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de PCHM?
Los precios de PCHM se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre PCHM?
La cobertura de analistas para PCHM incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en PCHM?
Las categorías de riesgo para PCHM incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory changes affecting the acceptance and use of sweat-based drug testing.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de PCHM?
La relación P/E para PCHM compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está PCHM sobrevalorada o infravalorada?
Determinar si PharmChem, Inc. (PCHM) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de PCHM?
PharmChem, Inc. (PCHM) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available on OTC-listed companies.
- Lack of analyst coverage for PCHM.
- Information based on available sources and may not be comprehensive.